Abstract 【Objective】To investigate the efficacy and safety of plasmakinetic enucleation of prostate (PKEP) in the treatment of massive benign prostatic hyperplasia.【Methods】A total of 112 patients with massive prostatic hyperplasia who were treated in our hospital from January 2020 to January 2021 were selected and divided into the observation group (n=56) and the control group (n=56).The patients in the observation group underwent PKEP, while the patients in the control group underwent transurethral plasma kinetic resection of prostate (TUPKP).The perioperative indexes and postoperative complications of the two groups of patients were compared. The patients were followed up for 3 months after the operation, then the follow-up related indexes, renal function, and sexual function of the two groups of patients before and after the operation were compared.【Results】The operation time, intraoperative blood loss, indwelling catheter time and hospital stay in the observation group were significantly shorter than those in the control group, and the weight of gland removal was significantly higher than that in the control group (P<0.05).The postoperative prostate symptom score (IPSS), quality of life score (QOL) and residual urine volume of the two groups were significantly lower than those before operation, and the maximum urinary flow rate was significantly higher than that before operation (P<0.05), but there were no significant differences of those parameters between the two groups (P>0.05).The postoperative blood urea nitrogen (BUN) and creatinine (Scr) of the two groups were significantly lower than those before the operation (P<0.05), however, there were no significantly different levels of BUN and Scr between the two groups (P>0.05).The scores of the International Index of Erectile Function (IIEF-5) at 6 months and 12 months after operation in the observation group were significantly lower than those before operation of the observation and those in the control group (P<0.05).The total incidence of complications in the observation group significantly lower than the control group (P<0.05).【Conclusion】The efficacy and safety of PKEP in the treatment of massive benign prostatic hyperplasia are good.
LI Junzhao,LI Jian,QI Chaoqun. Efficacy and Safety of PKEP in the Treatment of Massive Benign Prostatic Hyperplasia[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(1): 95-98.
[1] 刘红军,唐勇.良性前列腺增生的外科治疗进展[J].中国现代手术学杂志,2023,27(6):481-489. [2] 龙蠡,杨华伟,唐汇龙,等.刀口变向钬激光前列腺剜除术肌层无损伤解剖性松解膀胱颈治疗小体积前列腺增生[J].中国现代手术学杂志,2023,27(6):45-49. [3] JIANG Y L, QIAN L J. Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis[J].BMC Urol,2019, 19(1):11. [4] 向宸辉, 刘小勇, 王鹏桥,等. 经尿道等离子双极前列腺剜除术联合电切术治疗良性前列腺增生的临床对照研究[J].华南国防医学杂志, 2018, 32(5):318-320. [5] 张祥华, 王行环, 王刚,等. 良性前列腺增生临床诊治指南[J].中华外科杂志, 2007, 45(24):1704-1707. [6] UVAIS N A, MOHAMMED T P. Sertraline-associated acute urinary retention in a patient with benign prostatic hyperplasia[J].J Integrative Nephrol Androl,2021, 6(1):6-7. [7] BACH T, HEITZ M, BRUNS T. Benign prostatic hyperplasia : New and treatment-relevant aspects from the DGU guidelines[J].Der Urologe Ausg A,2020, 59(5):544-549. [8] BHOJANI N, ZORN K C, ELTERMAN D. A shared decision: Bipolar vs. monopolar transurethral resection of the prostate for benign prostatic hyperplasia[J].Can Urol Assoc J,2020, 14(12):431. [9] 关胜, 徐皖江, 蔡万松,等. 不同手术方案治疗高危良性前列腺增生症患者的疗效对比研究[J].中国性科学, 2019, 28(8):14-18. [10] 张伟, 陈其超, 冯欢,等. 经尿道等离子前列腺剜除术与经尿道前列腺电切术治疗良性前列腺增生症的临床疗效比较[J].东南国防医药, 2019, 21(6):649-651. [11] 喻小龙, 韩红甲. PKEP与HoLEP治疗老年良性前列腺增生的短期临床疗效比较[J].医学临床研究, 2021, 38(11):1647-1649. [12] 辛黎明. 经尿道前列腺等离子剜除术与电切术治疗前列腺增生的效果比较[J].中国医药导刊, 2021, 23(5):329-331. [13] 刘宏伟, 左玲, 柳建军,等. 经尿道等离子前列腺剜除术与电切术治疗大体积前列腺增生疗效比较[J].中国男科学杂志, 2015, 29(11):45-48. [14] 叶大文, 关超, 程涛. 经尿道前列腺等离子剜除术用于大体积前列腺增生患者的疗效和安全性研究[J].齐齐哈尔医学院学报, 2021, 42(1):37-40.
2025, Vol. 42 
